메뉴 건너뛰기




Volumn 8, Issue 4, 2014, Pages 1037-1048

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

A 0048 48; A 0048 58; B RAF KINASE INHIBITOR; INTERLEUKIN 6; JANUS KINASE; K RAS PROTEIN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; RANTES; RAS PROTEIN; RO 5126766; SELUMETINIB; SMALL INTERFERING RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BENZAMIDE DERIVATIVE; BRAF PROTEIN, HUMAN; CARBANILAMIDE DERIVATIVE; DIPHENYLAMINE; IL6 PROTEIN, HUMAN; NICOTINAMIDE; SORAFENIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

EID: 84908356209     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.07.010     Document Type: Article
Times cited : (61)

References (38)
  • 2
    • 34447506658 scopus 로고    scopus 로고
    • Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis
    • Ancrile B., Lim K.H., Counter C.M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007, 21:1714-1719.
    • (2007) Genes Dev. , vol.21 , pp. 1714-1719
    • Ancrile, B.1    Lim, K.H.2    Counter, C.M.3
  • 4
    • 0036857484 scopus 로고    scopus 로고
    • A scaleable synthesis of BAY 43-9006: a potent Raf kinase inhibitor for the treatment of cancer
    • Bankston D., Dumas J., Natero R., Riedl B., Monahan M.-K., Sibley R. A scaleable synthesis of BAY 43-9006: a potent Raf kinase inhibitor for the treatment of cancer. Org. Process Res. Dev. 2001, 6:777-781.
    • (2001) Org. Process Res. Dev. , vol.6 , pp. 777-781
    • Bankston, D.1    Dumas, J.2    Natero, R.3    Riedl, B.4    Monahan, M.-K.5    Sibley, R.6
  • 6
    • 84890644513 scopus 로고    scopus 로고
    • Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an invivo model of childhood astrocytoma
    • Bid H.K., Kibler A., Phelps D.A., Manap S., Xiao L., Lin J., Capper D., Oswald D., Geier B., DeWire M., et al. Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an invivo model of childhood astrocytoma. Clin. Cancer Res. 2013, 19:6716-6729.
    • (2013) Clin. Cancer Res. , vol.19 , pp. 6716-6729
    • Bid, H.K.1    Kibler, A.2    Phelps, D.A.3    Manap, S.4    Xiao, L.5    Lin, J.6    Capper, D.7    Oswald, D.8    Geier, B.9    DeWire, M.10
  • 10
    • 0033565832 scopus 로고    scopus 로고
    • Role of accurate mass measurement (+/- 10 ppm) in protein identification strategies employing MS or MS/MS and database searching
    • Clauser K.R., Baker P., Burlingame A.L. Role of accurate mass measurement (+/- 10 ppm) in protein identification strategies employing MS or MS/MS and database searching. Anal. Chem. 1999, 71:2871-2882.
    • (1999) Anal. Chem. , vol.71 , pp. 2871-2882
    • Clauser, K.R.1    Baker, P.2    Burlingame, A.L.3
  • 20
    • 84868314587 scopus 로고    scopus 로고
    • Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M
    • Illert A.L., Zech M., Moll C., Albers C., Kreutmair S., Peschel C., Bassermann F., Duyster J. Extracellular signal-regulated kinase 2 (ERK2) mediates phosphorylation and inactivation of nuclear interaction partner of anaplastic lymphoma kinase (NIPA) at G2/M. J.Biol. Chem. 2012, 287:37997-38005.
    • (2012) J.Biol. Chem. , vol.287 , pp. 37997-38005
    • Illert, A.L.1    Zech, M.2    Moll, C.3    Albers, C.4    Kreutmair, S.5    Peschel, C.6    Bassermann, F.7    Duyster, J.8
  • 22
    • 84859471412 scopus 로고    scopus 로고
    • Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies
    • Kudchadkar R., Paraiso K.H., Smalley K.S. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J. 2012, 18:124-131.
    • (2012) Cancer J. , vol.18 , pp. 124-131
    • Kudchadkar, R.1    Paraiso, K.H.2    Smalley, K.S.3
  • 27
    • 77949732073 scopus 로고    scopus 로고
    • RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
    • Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
    • (2010) Nature , vol.464 , pp. 427-430
    • Poulikakos, P.I.1    Zhang, C.2    Bollag, G.3    Shokat, K.M.4    Rosen, N.5
  • 29
    • 63149194964 scopus 로고    scopus 로고
    • (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
    • Pratilas C.A., Taylor B.S., Ye Q., Viale A., Sander C., Solit D.B., Rosen N. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 2009, 106:4519-4524.
    • (2009) Proc. Natl. Acad. Sci. USA , vol.106 , pp. 4519-4524
    • Pratilas, C.A.1    Taylor, B.S.2    Ye, Q.3    Viale, A.4    Sander, C.5    Solit, D.B.6    Rosen, N.7
  • 31
    • 84861178173 scopus 로고    scopus 로고
    • Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation
    • Schilling B., Rardin M.J., MacLean B.X., Zawadzka A.M., Frewen B.E., Cusack M.P., Sorensen D.J., Bereman M.S., Jing E., Wu C.C., et al. Platform-independent and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation. Mol. Cell. Proteomics 2012, 11:202-214.
    • (2012) Mol. Cell. Proteomics , vol.11 , pp. 202-214
    • Schilling, B.1    Rardin, M.J.2    MacLean, B.X.3    Zawadzka, A.M.4    Frewen, B.E.5    Cusack, M.P.6    Sorensen, D.J.7    Bereman, M.S.8    Jing, E.9    Wu, C.C.10
  • 32
    • 0029011218 scopus 로고
    • The MAPK signaling cascade
    • Seger R., Krebs E.G. The MAPK signaling cascade. FASEB J. 1995, 9:726-735.
    • (1995) FASEB J. , vol.9 , pp. 726-735
    • Seger, R.1    Krebs, E.G.2
  • 33
    • 3142676436 scopus 로고    scopus 로고
    • Overriding imatinib resistance with a novel ABL kinase inhibitor
    • Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
    • (2004) Science , vol.305 , pp. 399-401
    • Shah, N.P.1    Tran, C.2    Lee, F.Y.3    Chen, P.4    Norris, D.5    Sawyers, C.L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.